Skip to main content
. 2022 Dec 15;109(11):823–831. doi: 10.1136/heartjnl-2022-321885

Table 2.

Key baseline characteristics of patients enrolled in randomised controlled trials of IHM-guided HF management compared with standard care

COMPASS-HF CHAMPION REDUCE-HF LAPTOP-HF GUIDE-HF
Age (years) IHM arm: 58±14
Control arm: 58±13		 IHM arm: 61±13
Control arm: 62±13		 IHM arm: 55±15
Control arm: 55±15		 IHM and control arms: 62±12 IHM arm: 71 (64-76)
Control arm: 70 (64-77)
Sex (male, %) IHM arm: 66
Control arm: 64		 IHM arm: 72
Control arm: 73		 IHM arm: 70
Control arm: 67		 IHM and control arms: 75 IHM arm: 62
Control arm: 63
Race (%) IHM arm

  • White: 73


Control arm

  • White: 80

 IHM arm

  • White: 73


Control arm

  • White: 73

 IHM arm

  • White: 55


Control arm

  • White: 58

 n/r IHM arm

  • White: 81


Control arm

  • White: 80
EF (n=participants) ≥50%: 70
<50%: 204		 ≥50%: 66
≥40–49%: 53
≤40%: 456
<40%: 430		 IHM and control arms: mean EF 23%±7 IHM and control arms, EF >35%: 121
IHM and control arms, EF ≤35%: 365
Mean EF 30%±15		 >50%: 321
≤50%: 679
NYHA class (%) IHM arm:

  • III: 84

  • IV: 16


Control arm:

  • III: 87

  • IV: 13

 IHM arm: III only
Control arm: III only		 IHM arm:

  • II: 53

  • III: 47


Control arm:

  • II: 45

  • III: 55

 IHM arm: III only
Control arm: III only		 IHM arm:

  • II: 29

  • III: 65

  • IV: 6


Control arm:

  • II: 30

  • III: 65

  • IV: 5
Ischaemic aetiology (%) IHM arm: 47
Control arm: 44		 IHM arm: 59
Control arm: 62		 IHM arm: 45
Control arm: 44		 IHM and control arms: 46 IHM arm: 42
Control arm: 38
Diuretics (%) IHM arm: 93
Control arm: 99		 IHM arm: 92
Control arm: 92		 IHM arm: 93
Control arm: 97		 n/r IHM arm: 95
Control arm: 95
ACEi/ARB (%) IHM arm: 85
Control arm: 81		 IHM arm: 76
Control arm: 79		 IHM arm: 92
Control arm: 92		 n/r IHM arm*: 64
Control arm*: 64
Beta blockers (%) IHM arm: 83
Control arm: 81		 IHM arm: 90
Control arm: 91		 IHM arm: 96
Control arm: 96		 n/r IHM arm: 89
Control arm: 88

*ARNI/ACEi/ARB.

ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor blocker-neprilysin inhibitor; CHAMPION, CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association Class III Heart Failure Patients; COMPASS-HF, Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure; EF, ejection fraction; GUIDE-HF, Hemodynamic-Guided Management of Heart Failure; HF, heart failure; IHM, implantable haemodynamic monitoring; LAPTOP-HF, Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy; n/r, not reported; NYHA, New York Heart Association; REDUCE-HF, Reducing Events in Patients with Chronic Heart Failure.